Ana Slaughter
About
Ana Slaughter is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Ana Slaughter has authored 20 papers receiving a total of 50 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 11 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Ana Slaughter's work include Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (11 papers) and Cancer Treatment and Pharmacology (3 papers). Ana Slaughter is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (11 papers) and Cancer Treatment and Pharmacology (3 papers). Ana Slaughter collaborates with scholars based in Germany, Spain and United States. Ana Slaughter's co-authors include Kwee Yong, Nikoletta Lendvai, Philippe Moreau, Jordan M. Schecter, Hermann Einsele, Carolina Lonardi, Binod Dhakal, Jesús F. San Miguel, Katherine Li and Rakesh Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.
In The Last Decade
Ana Slaughter
17 papers receiving 49 citations
Peers
Ana Slaughter
Carolina Lonardi United States
Nitin Patel United States
Raphael Lutz Germany
Marta Reinoso Segura Spain
Titouan Cazaubiel France
Souhila Ikhlef France
Minna Suvela Finland
D. H. Vesole United States
Matteo Costacurta Australia
Sandra Martínez-Martín Spain
Citations per year, relative to Ana Slaughter Ana Slaughter (= 1×)
peers
Carolina Lonardi
Countries citing papers authored by Ana Slaughter
Since
Specialization
Citations
This map shows the geographic impact of Ana Slaughter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Slaughter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Slaughter more than expected).
Fields of papers citing papers by Ana Slaughter
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ana Slaughter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Slaughter. The network helps show where Ana Slaughter may publish in the future.
Co-authorship network of co-authors of Ana Slaughter
This figure shows the co-authorship network connecting the top 25 collaborators of Ana Slaughter. A scholar is included among the top collaborators of Ana Slaughter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Slaughter. Ana Slaughter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dhakal, Binod, Jinghua He, Jordan M. Schecter, et al.. (2025). Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database. Clinical Lymphoma Myeloma & Leukemia. 25(6). e394–e403.
2.
Costa, Luciano J., Katja Weisel, Surbhi Sidana, et al.. (2024). Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.. Journal of Clinical Oncology. 42(16_suppl). 7504–7504.
3.
Costa, Luciano J., Katja Weisel, Surbhi Sidana, et al.. (2024). MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 24. S569–S570.
4.
Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Advances. 8(19). 5062–5071.
5.
Mina, Roberto, Brian McClune, Noffar Bar, et al.. (2024). P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S74.
6.
Delforge, Michel, María‐Victoria Mateos, Kristina Carlson, et al.. (2024). Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma. Blood. 144(Supplement 1). 7085–7085.
7.
Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157.
8.
Costa, Luciano J., Katja Weisel, Surbhi Sidana, et al.. (2024). Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 24. S243–S243.
9.
Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2023). P-246 Real-world attrition rates after second-line therapy or later in patients from the flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide. Clinical Lymphoma Myeloma & Leukemia. 23. S171–S171.
10.
Dhakal, Binod, Kwee Yong, Simon J. Harrison, et al.. (2023). First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.. Journal of Clinical Oncology. 41(17_suppl). LBA106–LBA106.
11.
Dhakal, Binod, Hermann Einsele, Ravi Potluri, et al.. (2022). P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database. Clinical Lymphoma Myeloma & Leukemia. 22. S167–S167.
12.
Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2022). P-241: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database. Clinical Lymphoma Myeloma & Leukemia. 22. S168–S168.
13.
Siegel, David S., Niels W.C.J. van de Donk, Pieter Sonneveld, et al.. (2016). A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 34(15_suppl). TPS8072–TPS8072.
14.
Palumbo, Antonio, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY. Haematologica. 100. 82–83.
15.
Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. Haematologica. 100. 83–83.
16.
Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 15. e76–e77.
17.
Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 126(23). 4225–4225.
18.
Dimopoulos, Meletios Α., Antonio Palumbo, Katja Weisel, et al.. (2014). Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. Blood. 124(21). 80–80.
19.
Palumbo, Antonio, Meletios Α. Dimopoulos, Katja Weisel, et al.. (2014). Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. Blood. 124(21). 4770–4770.
20.
Dimopoulos, Meletios Α., Katja Weisel, Michèle Cavo, et al.. (2014). The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). TPS8625–TPS8625.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carolina Lonardi Breakdown of academic impact, for papers by Nitin Patel Breakdown of academic impact, for papers by Raphael Lutz Breakdown of academic impact, for papers by Marta Reinoso Segura Breakdown of academic impact, for papers by Titouan Cazaubiel Breakdown of academic impact, for papers by Souhila Ikhlef Breakdown of academic impact, for papers by Minna Suvela Breakdown of academic impact, for papers by D. H. Vesole Breakdown of academic impact, for papers by Matteo Costacurta Breakdown of academic impact, for papers by Sandra Martínez-Martín